首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1481812

全球生物工程蛋白药物市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Bioengineered Protein Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年05月07日 | 出版商:

Value Market Research | 英文 234 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球生物工程蛋白药物市场需求预计将从 2023 年的 3,467.6 亿美元达到近 6,455.9 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 7.15%。

生物工程蛋白质药物是利用生物技术生产模仿体内自然存在的蛋白质的药品。这些药物针对疾病过程中涉及的特定生物途径或分子，为自体免疫疾病、癌症和遗传性疾病等各种医疗状况提供标靶治疗。这些药物是利用重组 DNA 技术生产的，其中编码所需蛋白质的基因被插入宿主细胞中，如酵母、细菌或哺乳动物细胞，这些细胞充当微型蛋白质工厂。与传统药物相比，这些药物提供高效、更有针对性且副作用更少的疗法，彻底改变了医学治疗。

市场动态

癌症、自体免疫疾病和代谢疾病等慢性病的盛行率不断上升，推动了对标靶生物疗法的需求，这些疗法比传统药物可提高疗效并减少副作用。生物工程蛋白质药物，包括单株抗体、细胞激素和生长因子，可以精确靶向和调节疾病途径，从而改善患者的治疗结果和生活品质。此外，生物技术和基因工程技术的进步使得能够开发出具有增强效力、特异性和稳定性的新型蛋白质疗法，从而扩大了患者和医疗保健提供者可用的治疗选择。此外，生物製药公司和学术机构对研发的投资不断增加，正在推动生物工程蛋白质药物发现和开发的创新，从而发现新的药物标靶和治疗方式。此外，越来越多地采用个人化医疗方法和生物标记驱动的治疗策略，推动了对根据个别患者特征和疾病概况定制的生物工程蛋白药物的需求，从而改善治疗结果并降低医疗成本。包括 FDA 和 CMS 在内的监管机构和付款人越来越接受生物工程蛋白药物，这促进了这些创新疗法的市场准入和报销，进一步推动了市场成长和采用。然而，生物製药和替代治疗方式的进步可能会挑战未来几年的市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球生物工程蛋白药物市场的各个细分市场进行了包容性评估。生物工程蛋白药物产业的成长和趋势为这项研究提供了整体方法。

市场区隔

生物工程蛋白药物市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略家确定相应产品或服务的目标人口统计数据以及即将到来的机会。

依药物类型

单株抗体（Humira、Rituxan、Avastin、Herceptin、Remicade、Lucentis、Enbrel、Synazis 等）
治疗性蛋白质（荷尔蒙、细胞激素（Neupogen、Neulasta、干扰素α、红血球生成素α、白血球介素等）血液因子、酵素疗法（全身性酵素疗法、消化酵素疗法）、血栓溶解剂（tPA链激酶、尿激酶））
疫苗

按病情

癌症
糖尿病
自体免疫疾病
传染病
造血作用
CVD
神经退化性疾病
其他的

按最终用户

製药和生物技术公司
合约研究组织
研究机构

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲生物工程蛋白药物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。生物工程蛋白药物市场的主要参与者包括雅培、安进公司、拜耳公司、Biocon、雷迪博士实验室、礼来公司、F.霍夫曼-拉罗氏有限公司、费森尤斯卡比公司、葛兰素史克、杨森全球服务公司、默克公司. Inc.、诺华公司、Panacea Biotec、ProBioGen AG、Reliance Life Science、赛诺菲。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

按药物类型概述
历史和预测数据
依药物类型分析
单株抗体（Humira、Rituxan、Avastin、Herceptin、Remicade、Lucentis、Enbrel、Synazis 等）
治疗性蛋白质（荷尔蒙、细胞激素（Neupogen、Neulasta、干扰素α、红血球生成素α、白血球介素等）血液因子、酵素疗法（全身性酵素疗法、消化酵素疗法）、血栓溶解剂（tPA链激酶、尿激酶））
疫苗

第 6 章：全球生物工程蛋白药物市场分析：依疾病状况

按疾病状况概述
历史和预测数据
按病情分析
癌症
糖尿病
自体免疫疾病
传染病
造血作用
CVD
神经退化性疾病
其他的

第 7 章：全球生物工程蛋白药物市场分析：依最终使用者分类

最终用户概述
历史和预测数据
最终用户分析
製药和生物技术公司
合约研究组织
研究机构

第 8 章：全球生物工程蛋白药物市场分析：依地理位置

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：生物工程蛋白药物公司的竞争格局

生物工程蛋白质药物市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

顶级公司市占率分析
市场集中度
Abbott

公司简介
公司收入
产品
最近的发展

Amgen Inc.

公司简介
公司收入
产品
最近的发展

Bayer AG

公司简介
公司收入
产品
最近的发展

Biocon

公司简介
公司收入
产品
最近的发展

Dr. Reddy'S Laboratories

公司简介
公司收入
产品
最近的发展

Lilly

公司简介
公司收入
产品
最近的发展

F. Hoffmann - La Roche Ltd.

公司简介
公司收入
产品
最近的发展

Fresenius Kabi AG

公司简介
公司收入
产品
最近的发展

公司简介
公司收入
产品
最近的发展

Janssen Global Services

公司简介
公司收入
产品
最近的发展

Merck & Co. Inc.

公司简介
公司收入
产品
最近的发展

Novartis AG

公司简介
公司收入
产品
最近的发展

Panacea Biotec

公司简介
公司收入
产品
最近的发展

ProBioGen AG

公司简介
公司收入
产品
最近的发展

Reliance Life Science

公司简介
公司收入
产品
最近的发展

Sanofi

公司简介
公司收入
产品
最近的发展

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112114477

The global demand for Bioengineered Protein Drugs Market is presumed to reach the market size of nearly USD 645.59 Billion by 2032 from USD 346.76 Billion in 2023 with a CAGR of 7.15% under the study period 2024-2032.

Bioengineered protein drugs are pharmaceutical products created using biotechnology techniques to produce proteins that mimic those naturally occurring in the body. These drugs target specific biological pathways or molecules involved in disease processes, offering targeted therapies for various medical conditions such as autoimmune disorders, cancer, and genetic diseases. These drugs are produced using recombinant DNA technology, where genes encoding the desired protein are inserted into host cells such as yeast, bacteria, or mammalian cells, which act as miniature protein factories. These drugs have revolutionized medical treatment by providing highly effective and often more targeted therapies with fewer side effects compared to traditional drugs.

MARKET DYNAMICS

The proliferating prevalence of chronic diseases such as cancer, autoimmune disorders, and metabolic diseases is driving the demand for targeted and biologically-based therapies that offer enhanced efficacy & reduced side effects than traditional pharmaceuticals. Bioengineered protein drugs, including monoclonal antibodies, cytokines, and growth factors, provide precise targeting and modulation of disease pathways, leading to better patient outcomes and quality of life. Additionally, advancements in biotechnology and genetic engineering techniques allow the development of novel protein therapeutics with enhanced potency, specificity, and stability, expanding the therapeutic options available to patients and healthcare providers. Moreover, the growing investment in research and development by biopharmaceutical companies and academic institutions is driving innovation in bioengineered protein drug discovery and development, leading to the discovery of novel drug targets and therapeutic modalities. Furthermore, the increasing adoption of personalized medicine approaches and biomarker-driven treatment strategies drives demand for bioengineered protein drugs tailored to individual patient characteristics and disease profiles, improving treatment outcomes and reducing healthcare costs. The growing acceptance of bioengineered protein drugs by regulatory agencies and payers, including the FDA and CMS, facilitates market access and reimbursement for these innovative therapies, further driving market growth and adoption. However, advancements in biopharmaceuticals and alternative treatment modalities may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Bioengineered Protein Drugs. The growth and trends of Bioengineered Protein Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Bioengineered Protein Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

Monoclonal Antibodies (Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, Synazis, Others)
Therapeutic Proteins (Hormones, Cytokines(Neupogen, Neulasta, Interferon Alpha, Erythropoietin Alpha, Interleukin, Others) Blood Factor, Enzyme Therapy (Systemic Enzyme Therapy, Digestive Enzyme Therapy), Thrombolytics (tPA Streptokinase, Urokinase))
Vaccines

By Disease Condition

Cancer
Diabetes
Autoimmune Disorder
Infectious Disease
Hematopoiesis
CVD
Neurodegenerative
Others

By End-user

Pharma and Biotech Companies
CROs
Research Institutes

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Bioengineered Protein Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Bioengineered Protein Drugs market include Abbott, Amgen Inc., Bayer AG, Biocon, Dr. Reddy'S Laboratories, Lilly, F. Hoffmann - La Roche Ltd., Fresenius Kabi AG, GSK, Janssen Global Services, Merck & Co. Inc., Novartis AG, Panacea Biotec, ProBioGen AG, Reliance Life Science, Sanofi. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. BIOENGINEERED PROTEIN DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Disease Condition
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET ANALYSIS BY DRUG TYPE

5.1. Overview By Drug Type
5.2. Historical and Forecast Data
5.3. Analysis By Drug Type
5.4. Monoclonal Antibodies (Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, Synazis, Others) Historic and Forecast Sales By Regions
5.5. Therapeutic Proteins (Hormones, Cytokines(Neupogen, Neulasta, Interferon Alpha, Erythropoietin Alpha, Interleukin, Others) Blood Factor, Enzyme Therapy (Systemic Enzyme Therapy, Digestive Enzyme Therapy), Thrombolytics (tPA Streptokinase, Urokinase)) Historic and Forecast Sales By Regions
5.6. Vaccines Historic and Forecast Sales By Regions

6. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET ANALYSIS BY DISEASE CONDITION

6.1. Overview By Disease Condition
6.2. Historical and Forecast Data
6.3. Analysis By Disease Condition
6.4. Cancer Historic and Forecast Sales By Regions
6.5. Diabetes Historic and Forecast Sales By Regions
6.6. Autoimmune Disorder Historic and Forecast Sales By Regions
6.7. Infectious Disease Historic and Forecast Sales By Regions
6.8. Hematopoiesis Historic and Forecast Sales By Regions
6.9. CVD Historic and Forecast Sales By Regions
6.10. Neurodegenerative Historic and Forecast Sales By Regions
6.11. Others Historic and Forecast Sales By Regions

7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET ANALYSIS BY END-USER

7.1. Overview By End-user
7.2. Historical and Forecast Data
7.3. Analysis By End-user
7.4. Pharma and Biotech Companies Historic and Forecast Sales By Regions
7.5. CROs Historic and Forecast Sales By Regions
7.6. Research Institutes Historic and Forecast Sales By Regions

8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE BIOENGINEERED PROTEIN DRUGS COMPANIES

9.1. Bioengineered Protein Drugs Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF BIOENGINEERED PROTEIN DRUGS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Abbott
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Amgen Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Bayer AG
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Biocon
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Dr. Reddy'S Laboratories
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Lilly
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. F. Hoffmann - La Roche Ltd.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Fresenius Kabi AG
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. GSK
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Janssen Global Services
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Merck & Co. Inc.
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. Novartis AG
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments
10.15. Panacea Biotec
- 10.15.1 Company Overview
- 10.15.2 Company Revenue
- 10.15.3 Products
- 10.15.4 Recent Developments
10.16. ProBioGen AG
- 10.16.1 Company Overview
- 10.16.2 Company Revenue
- 10.16.3 Products
- 10.16.4 Recent Developments
10.17. Reliance Life Science
- 10.17.1 Company Overview
- 10.17.2 Company Revenue
- 10.17.3 Products
- 10.17.4 Recent Developments
10.18. Sanofi
- 10.18.1 Company Overview
- 10.18.2 Company Revenue
- 10.18.3 Products
- 10.18.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

简介目录图表

LIST OF TABLES

Market Snapshot
Drivers: Impact Analysis
Restraints: Impact Analysis
List of Raw Material
List of Raw Material Manufactures
Analysis By Drug Type (USD MN)
Monoclonal Antibodies (Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, Synazis, Others) Market Sales By Geography (USD MN)
Therapeutic Proteins (Hormones, Cytokines(Neupogen, Neulasta, Interferon Alpha, Erythropoietin Alpha, Interleukin, Others) Blood Factor, Enzyme Therapy (Systemic Enzyme Therapy, Digestive Enzyme Therapy), Thrombolytics (tPA Streptokinase, Urokinase)) Market Sales By Geography (USD MN)
Vaccines Market Sales By Geography (USD MN)
Analysis By Disease Condition (USD MN)
Cancer Market Sales By Geography (USD MN)
Diabetes Market Sales By Geography (USD MN)
Autoimmune Disorder Market Sales By Geography (USD MN)
Infectious Disease Market Sales By Geography (USD MN)
Hematopoiesis Market Sales By Geography (USD MN)
CVD Market Sales By Geography (USD MN)
Neurodegenerative Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Analysis By End-user (USD MN)
Pharma and Biotech Companies Market Sales By Geography (USD MN)
CROs Market Sales By Geography (USD MN)
Research Institutes Market Sales By Geography (USD MN)
Global Bioengineered Protein Drugs Market Sales By Geography (USD MN)
North America Market Analysis (USD MN)
United States Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate By Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
South East Asia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition

LIST OF FIGURES

Research Scope of Bioengineered Protein Drugs Report
Market Research Process
Market Research Methodology
Global Bioengineered Protein Drugs Market Size, By Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis By Drug Type
Market Attractiveness Analysis By Disease Condition
Market Attractiveness Analysis By End-user
Market Attractiveness Analysis By Region
Value Chain Analysis
Global Market Analysis By Drug Type (USD MN)
Monoclonal Antibodies (Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, Synazis, Others) Market Sales By Geography (USD MN)
Therapeutic Proteins (Hormones, Cytokines(Neupogen, Neulasta, Interferon Alpha, Erythropoietin Alpha, Interleukin, Others) Blood Factor, Enzyme Therapy (Systemic Enzyme Therapy, Digestive Enzyme Therapy), Thrombolytics (tPA Streptokinase, Urokinase)) Market Sales By Geography (USD MN)
Vaccines Market Sales By Geography (USD MN)
Global Market Analysis By Disease Condition (USD MN)
Cancer Market Sales By Geography (USD MN)
Diabetes Market Sales By Geography (USD MN)
Autoimmune Disorder Market Sales By Geography (USD MN)
Infectious Disease Market Sales By Geography (USD MN)
Hematopoiesis Market Sales By Geography (USD MN)
CVD Market Sales By Geography (USD MN)
Neurodegenerative Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Market Analysis By End-user (USD MN)
Pharma and Biotech Companies Market Sales By Geography (USD MN)
CROs Market Sales By Geography (USD MN)
Research Institutes Market Sales By Geography (USD MN)
Global Market Sales (USD MN)
North America Market Sales (USD MN)
Europe Market Sales (USD MN)
Asia Pacific Market Sales (USD MN)
Latin America Market Sales (USD MN)
Middle East & Africa Market Sales (USD MN)
Recent Development in Industry
Top Company Market Share Analysis